Companies
Viatris
S&P 500Health Care· USA

VTRS

Balancer

Viatris

BAL

$13.83

+2.67%

Open $13.38·Prev $13.47

as of 13 Apr

BALANCER

Power Core

Viatris's moat is the sheer breadth of its global distribution infrastructure across 165 countries, paired with a portfolio of 1,400-plus molecules that no single competitor can replicate at equivalent scale.

Published1 Apr 2026
UniverseS&P 500
SectorHealth Care

Direction of Movement

Lateral: Between Restructuring Completion and Growth Proof

ROC 200

+49.5%

Company Profile

Viatris Inc. is a global healthcare company that develops, manufactures, and markets a broad portfolio of branded and generic pharmaceutical products. It specializes in generics, including commoditized and complex varieties as well as biosimilars, alongside legacy branded medicines such as Lipitor, Norvasc, Lyrica, and Viagra. The company addresses multiple therapeutic areas, including cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare, with particular focus on dermatology, ophthalmology, and gastroenterology. Viatris Inc. serves patients in over 165 countries through its extensive product offerings in the specialty and generic drug sectors. Founded in 2019 and headquartered in Canonsburg, Pennsylvania, it operates as one of the largest generic drug manufacturers worldwide, providing essential medicines and treatments to diverse healthcare markets.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

30,000

This page is for informational purposes only and does not constitute investment advice. L17X Research is an independent research service.